National Drug Code Directory
|
|
|
- Rosa Chapman
- 7 years ago
- Views:
Transcription
1 The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or processed by it for commercial distribution. (See Section 510 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. 360)). Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. FDA publishes the listed NDC numbers and the information submitted as part of the listing information in the NDC Directory which is updated daily. 2016
2 Gold Bond Ultimate Hand Sanitizer Moisturizer Labeler Chattem, Inc. of Company corresponding to the labeler code segment of the ProductNDC. NDC Code The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC. Proprietary Gold Bond Ultimate Hand Sanitizer Moisturizer Also known as the trade name. It is the name of the product chosen by the labeler. 11 Digit NDC Code It should be noted that many NDCs are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a format. Converting NDCs from a 10-digit to 11-digit format requires a strategically placed zero, dependent upon the 10-digit format. Product NDC The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. Product Type Non Proprietary Package Description Marketing Category Application Number HUMAN OTC DRUG Benzethonium Chloride 76 g in 1 TUBE ( ) OTC MONOGRAPH NOT FINAL part333 Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the Document Type of the SPL submission for the listing. The complete list of codes and translations can be found at under Structured Product Labeling Resources. Sometimes called the generic name, this is usually the active ingredient(s) of the product. A description of the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. For example: 4 BOTTLES in 1 CARTON/100 TABLETS in 1 BOTTLE. Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at under Structured Product Labeling Resources. This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. part 341 ). For unapproved drugs, this field will be null
3 Start Marketing Date This is the date that the labeler indicates was the start of its marketing of the drug product. Dosage Form LOTION The translation of the DosageForm Code submitted by the firm. The complete list of codes and translations can be found under Structured Product Labeling Resources. Route TOPICAL The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at under Structured Product Labeling Resources. Substance BENZETHONIUM CHLORIDE This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. Strength Number.2 These are the strength values (to be used with units below) of each active ingredient, listed in the same order as the Substance field above. Strength Unit g/100g These are the units to be used with the strength values above, listed in the same order as the Substance and SubstanceNumber
4 Food and Drug Administration Center for Drug Evaluation and Research Office of Compliance, Immediate Office Drug Registration and Listing Team New Hampshire Ave Silver Spring, MD
5 For all questions regarding this bundle please contact Also feel free to let us know about any suggestions or concerns. All additional information as well as customer support is available at
National Drug Code Directory
The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or
Content of Labeling/Product Data Elements SPL Technical Errors Training ebook
Content of Labeling/Product Data Elements SPL Technical s Training ebook Interpretations & s for Technical s in Content of Labeling/Product Data Elements SPL Documents Submitted to FDA Version 1.0 Purpose:
Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Guidance for Industry
Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for
Guidance for Industry
Guidance for Industry Providing Regulatory Submissions in Electronic Format Drug Establishment Registration and Drug Listing U.S. Department of Health and Human Services Food and Drug Administration Office
CENTER FOR DRUG EVALUATION AND RESEARCH. 203551Orig1s000
CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: Trade Name: Generic Name: Sponsor: 203551Orig1s000 Docetaxel Injection Concentrate, 20 mg/ml, 80 mg/4 ml, 140 mg/7 ml.
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC
Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions
IACP Comparison of 503A and 503B The Drug Quality and Security Act of 2013
Exempt Sections within the Food, Drug, and Cosmetic Act If a "traditional compounder", defined as a licensed pharmacist or licensed physician, meets ALL conditions within Section 503A, the compounder is
Guidance for Industry
Guidance for Industry Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications Small Entity Compliance Guide U.S. Department of
Guidance for Industry
Guidance for Industry Medication Guides Adding a Toll-Free Number for Reporting Adverse Events U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator,
Reprinted from FDA s website by Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, Guidance And Antiasthmatic for Drug Industry Products for Over-the-Counter Labeling
Recommended Warning for Overthe-Counter. Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions
Recommended Warning for Overthe-Counter Acetaminophen- Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions Guidance for Industry DRAFT GUIDANCE This guidance document is being
OV E R V I E W A N D G U I D A N C E O N VACC I N E 2 D B A R CO D I N G
Vada Perkins, BSN, MSc, RN CAPT, USPHS, Chief, Business Operations Staff US Food and Drug Administration OV E R V I E W A N D G U I D A N C E O N VACC I N E 2 D B A R CO D I N G "Reviewed April 2013" 2D
Guidance for Industry
Guidance for Industry Submitting Debarment Certification Statements DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
Establishment Registration SPL Technical Errors Training ebook
Technical Errors Training ebook Interpretations & s for Technical Errors in Establishment Registration SPL Documents Submitted to FDA Version 1.0 Purpose: This SPL training ebook is to be utilized by SPL
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products
Guidance for Industry Time and Extent Applications for Nonprescription Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
NDA 021879 NDA APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021879 NDA APPROVAL Avanir Pharmaceuticals Attention: Randall Kaye, M.D. Vice President, Clinical and Medical
Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice
Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice Kurt R. Karst Hyman, Phelps & McNamara, P.C. 700 Thirteenth Street, N.W., Suite 1200 Washington, D.C.
Guidance for Industry Bar Code Label Requirements Questions and Answers
Guidance for Industry Bar Code Label Requirements Questions and Answers For questions on the content of this guidance, contact the Center for Drug Evaluation and Research or the Center for Biologics Evaluation
On May 8 and 9, 2014, FDA held a public workshop on the development of initial standards for
The Drug Supply Chain Security Act Implementation: FDA s Public Workshop on Developing Standards for the Interoperable Exchange of Information for Tracing of Human, Finished, Prescription Drugs, in Paper
NDA 202439/S-008 SUPPLEMENT APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 202439/S-008 SUPPLEMENT APPROVAL Janssen Pharmaceuticals, Inc. ATTENTION: Alla Rhoge Pharm.D., Associate
Guidance for Industry
Guidance for Industry Providing Regulatory Submissions in Electronic Format Content of Labeling U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
Average Sale Price (ASP) Data Collection Template/Data Validation Macro User Manual
Centers for Medicare & Medicaid Services Center for Medicare (CM) Hospital and Ambulatory Policy Group 7500 Security Blvd Baltimore, MD 21244-1850 Average Sale Price (ASP) Data Collection Template/Data
Members covered under the Extended Family Planning (EFP) plan may not be eligible for all services. EFP is not a comprehensive benefit package.
PHARMACEUTICALS NDC BILLING REQUIREMENTS POLICY This policy applies to Participating and Non-participating providers who render services to Neighborhood Health Plan of Rhode Island (Neighborhood) subscribers
Coding Systems. Understanding NDC and HCPCS. December 2014
Coding Systems Understanding NDC and HCPCS December 2014 White Paper Coding Systems Understanding NDC and HCPCS National Drug Code The National Drug Code (NDC) serves as a universal product identifier
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
Food and Drug Administration
Center for Drug Evaluation and Research (CDER) Small Business Assistance Program The Information Source for Regulated Domestic and International Small Pharmaceutical Business CAPT Brenda Stodart, USPHS
DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers
DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for
Application Submitted on Received on Supplement type NDA 021875/S-005 July 24, 2008 July 25, 2008 Changes Being Effected
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021875/S-005, S-008, S-015 SUPPLEMENT APPROVAL Cephalon Inc. Attention: Paul Kirsch Senior Director and Group
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry The portion of this guidance document setting forth the submission procedures for risk evaluation and mitigation
February 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
Inspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Jabones Pardo S.A.
Guidance for Industry
Guidance for Industry Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
Guidance for Industry
Guidance for Industry Applications Covered by Section 505(b)(2) DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document
Guidance for Industry
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle
FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle Kurt R. Karst Associate Hyman, Phelps & McNamara, P.C. 700 Thirteenth
May 5, 2015. Dear Mr. Courtney:
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 May 5, 2015 Terumo Cardiovascular
New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products
New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff
Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff Document issued on August 20, 2014. On November 5, 2014 this document was
Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program
Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program DRAFT GUIDANCE This guidance document is being distributed for comment purposes
Billing with National Drug Codes (NDCs) Frequently Asked Questions
Billing with National Drug Codes (NDCs) Frequently Asked Questions NDC Overview Converting HCPCS/CPT Units to NDC Units Submitting NDCs on Professional/Ancillary Claims Reimbursement Details For More Information
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications DRAFT GUIDANCE This guidance document is being distributed
Guidance for Industry Classifying Resubmissions in Response to Action Letters
Guidance for Industry Classifying Resubmissions in Response to Action Letters U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Providing Regulatory Submissions in Electronic and Non-Electronic Format Promotional Labeling and Advertising Materials for Human Prescription Drugs Guidance for Industry DRAFT GUIDANCE This guidance document
Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009
Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry DRAFT GUIDANCE This guidance document is being
Guidance for Industry
Guidance for Industry Best Practices in Developing Proprietary Names for Drugs DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
Guidance for Industry DRAFT GUIDANCE
DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information Guidance for Industry DRAFT GUIDANCE
Billing with National Drug Codes (NDCs) Frequently Asked Questions
Billing with National Drug Codes (NDCs) Frequently Asked Questions NDC Overview Converting HCPCS/CPT Units to NDC Units Submitting NDCs on Professional Claims Reimbursement Details For More Information
Medical Devices; Cardiovascular Devices; Classification of the Esophageal Thermal Regulation
This document is scheduled to be published in the Federal Register on 08/18/2015 and available online at http://federalregister.gov/a/2015-20317, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Medical Device Data Systems, Medical Image Storage Devices, and Medical Image
4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-D-0798] Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communication Devices;
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions U.S. Department of Health and Human Services Food and Drug Administration
Determination of Regulatory Review Period for Purposes of Patent Extension; XARELTO
This document is scheduled to be published in the Federal Register on 05/29/2014 and available online at http://federalregister.gov/a/2014-12349, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN
2014 Annual Report on Inspections of Establishments
2014 Annual Report on Inspections of Establishments Table of Contents Introduction... 2 Data Collection and Definitions... 3 Section 510(h)(6)(A)(i) Number of Domestic and Foreign Establishments Registered
ExCPT Certified Pharmacy Technician (CPhT) Detailed Test Plan* 100 scored items, 20 pretest items Exam time: 2 hours 10 minutes
ExCPT Certified Pharmacy Technician (CPhT) Detailed Test Plan* 100 scored items, 20 pretest items Exam time: 2 hours 10 minutes # scored items 1. Regulations and Pharmacy Duties 35 A. Overview of technician
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
April 10, 2008 Montana Healthcare Programs Update
April 10, 2008 Montana Healthcare Programs Update THE FOLLOWING INFORMATION UPDATES AND REPLACES THE PROVIDER NOTICE DATED MARCH 10, 2008. NEW OR REVISED INFORMATION IS MARKED WITH A CHANGE BAR IN THE
POLICY AND PROCEDURES OFFICE OF THE CENTER DIRECTOR. Table of Contents
POLICY AND PROCEDURES OFFICE OF THE CENTER DIRECTOR Tracking of Significant Safety issues in Marketed Drugs -- Use of the DARRTS Tracked Safety Issues Table of Contents PURPOSE...1 BACKGROUND...1 POLICY...2
School of Pharmacy TEMPLE UNIVERSITY
School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme
0 EC2 92011 V-,) 133 Lj9a
0 EC2 92011 V-,) 133 Lj9a Section 5: 5 1 0(k) Summar 5 10(K) SUMMARY FOR SOMATOM DEFINITION Flash (with Stellar Detector) Submitted by: Siemens Medical Solutions USA, Inc. 51 Valley Stream Parkway Malvern,
Instructions for Completing the Initial System Assessment for Upcoming HIPAA Changes Due Date: (specify date)
for Completing the Initial System Assessment for Upcoming HIPAA Changes Due Date: (specify date) Some major changes to the HIPAA federally mandated regulations are forthcoming. Therefore, it is essential
RE: NDA: 021876 DICLEGIS (doxylamine succinate and pyridoxine hydrochloride) delayed-release tablets, for oral use MA # 350 WARNING LETTER
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Eric Gervais, Executive Vice President 919 Conestoga Road Building
Determination of Regulatory Review Period for Purposes of Patent Extension;
This document is scheduled to be published in the Federal Register on 12/15/2015 and available online at http://federalregister.gov/a/2015-31400, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Standards for the Interoperable Exchange of Information for Tracing of Human, Finished,
4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-N-0337] Standards for the Interoperable Exchange of Information for Tracing of Human, Finished, Prescription
Enclosure A DEFINITIONS
Enclosure A REBATE AGREEMENT Between The Secretary of Health and Human Services (hereinafter referred to as "the Secretary") and The Manufacturer Identified in Section XI of this Agreement (hereinafter
Guidance for Industry Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act
Guidance for Industry Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act DRAFT GUIDANCE This guidance document is being distributed for comment purposes
January 12, 2016. Dear Amy Yang:
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 January 12, 2016 Amy
Guidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)
Guidance s Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
November 20, 2014. Vascular Flow Technologies Ltd. Edwin Lindsay VP of QA/RA Prospect Business Centre, Gemini Cresent Dundee DD2 1TY United Kingdom
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 November 20, 2014 Vascular
Guidance for Industry
Guidance for Industry Labeling for Human Prescription Drug and Biological Products Implementing the PLR Content and Format Requirements U.S. Department of Health and Human Services Food and Drug Administration
The 505(b)(2) Drug Development Pathway:
The 505(b)(2) Drug Development Pathway: When and How to Take Advantage of a Unique American Regulatory Pathway By Mukesh Kumar, PhD, RAC and Hemant Jethwani, MS The 505(b)(2) regulation offers a less expensive
Recommendations from Past Reports: E Prescribing Standards
Recommendations from Past Reports: Recommendation Report Implemented? HHS should ensure that e prescribing standards are not only appropriate for Medicare Part D but also for all types of prescribers,
Guidance for Industry Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification
Guidance for Industry Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
Massachusetts Department of Public Health (MDPH) Prescription Monitoring Program (MA PMP) and Drug Control Program (DCP) April 8, 2014
MA PMP Pharmacy Data Entry and Data Submitter s FAQ Utilizing ASAP 4.2 Supplement to the MA PMP Pharmacy Data Entry and Data Submitter s Guide Utilizing ASAP 4.2 Massachusetts Department of Public Health
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Internet/Social Media Platforms with Character Space Limitations Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document
Home Use Medical Device Electronic Labeling - Structured Product Labeling
Home Use Medical Device Electronic Labeling - Structured Product Labeling Device Labeling Public Workshop - April 2013 Lonnie Smith Policy Analyst U.S. FDA Data Standards Council Overview Home Use Medical
Guidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50.
Guidance for Sponsors, Investigators, and Institutional Review Boards Questions and Answers on Informed Consent Elements, 21 CFR 50.25(c) (Small Entity Compliance Guide) U.S. Department of Health and Human
TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER H--MEDICAL DEVICES
[Code of Federal Regulations] [Title 21, Volume 8] [Revised as of April 1, 2010] [CITE: 21CFR807] TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES
CATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity
CATEGORY Advertising Guidance Agenda: New & Guidances CDER is Planning to Publish During Calendar Year 2016 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details
Request for Quality Metrics Guidance for Industry
Request for Quality Metrics Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be
Pharmaceutical development is an expensive, time
Exclusivity Strategies in the United States and European Union by Carolyne Hathaway, John Manthei and Cassie Scherer Pharmaceutical development is an expensive, time consuming and uncertain process that
April 7, 2015. Acclarent, Inc. Mr. James Patrick Garvey II Sr. Manager, Regulatory Affairs 1525-B O'Brien Drive Menlo Park, CA 94025
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 April 7, 2015 Acclarent,
Medical Billing and Agency Formal Disputes
Guidance for Industry Formal Dispute Resolution: Appeals Above the Division Level Additional copies of this Guidance are available from: Office of Training and Communications Division of Communications
THE FOOD AND DRUG ADMINISTRATION S NATIONAL DRUG CODE DIRECTORY
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL THE FOOD AND DRUG ADMINISTRATION S NATIONAL DRUG CODE DIRECTORY Daniel R. Levinson Inspector General August 2006 OEI-06-05-00060 Office
Prescription Drug Rider
Prescription Drug Rider This Rider is part of the Evidence of Coverage and is effective on the date Your group is effective or renews its coverage with Southern Health Services, Inc. Benefits are available
Small Business Assistance
Small Business Assistance Products Ronald.Wilson@fda.hhs.gov Financial Assistance and Incentives for Research and Development of New Drug/Biologic Ron Wilson, Director of Small Business Assistance Center
Drug Imports Exports Compliance
Drug Imports Exports Compliance 1 CDER Office of Compliance Office of Drug Security, Integrity & Recalls Division of Import Operations & Recalls Imports Exports Compliance Branch FDA compliance focal point
May 7, 2015. Tactile Systems Technology Inc Daniel Chase V.P. Engineering & Operations 1331 Tyler St NE Minneapolis, Minnesota 55413
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 May 7, 2015 Tactile Systems Technology Inc Daniel
Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs
Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs Drug Information Journal 00(0) 1-6 ª The Author(s) 2012
Cosmetics Regulation in the United States and the European Union:
Cosmetics Regulation in the United States and the European Union: Different Pathways to the Same Result By Richard Kingham and Lucas E. Beirne Introduction It is sometimes suggested that cosmetic products
Combination Products Regulation in the United States
Combination Products Regulation in the United States Presenter: Scott Sardeson RAC US/EU 3M Health Care St. Paul, MN USA 1 Presentation Outline Combination products Definitions and Regulations Jurisdiction
Guidance for Industry
Guidance for Industry Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices DRAFT GUIDANCE This guidance document is being distributed
Notes on the architecture, design, and data processes in openfda. processing, data harmonization, and website technologies.
Notes on the architecture, design, and data processes in openfda OpenFDA uses cutting edge technologies and is a pilot for how FDA can develop and deploy novel applications in the public cloud securely
Medical Gas Compliance Alert
31 January 2013 rev. 7/14/2015 Medical Gas Compliance Alert Medical Gas Certification Important Compliance Alert Medical Gas Certification This GAWDA Medical Gas Compliance Alert is to inform GAWDA members
Providing Regulatory Submissions In Electronic Format Standardized Study Data
Providing Regulatory Submissions In Electronic Format Standardized Study Data Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Good Review Practice. October 2009 Labeling
Guidance for Industry and Review Staff Labeling for Human Prescription Drug and Biological Products Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information Good
Thomas Hinchliffe, Pharm.D. CDR, U.S. Public Health Service Special Assistant to the Director Office of Generic Drugs Food and Drug Administration
Thomas Hinchliffe, Pharm.D. CDR, U.S. Public Health Service Special Assistant to the Director Office of Generic Drugs Food and Drug Administration Disclaimer & Disclosure Views presented are those of the
Compendium service companies assemble and. They add a zero to result in a consistent 11-digit
200 maximize the usefulness of this information. Compendium service companies assemble and distribute information to retail stores, hospitals, prescription benefit managers (PBMs), insurance companies,
Active ingredient Stannous fluoride 0.63% w/w (0.19% w/v flouride ion) Purpos e anticavity, antigingivitis, antihypersensitivity, mouthrinse
PERIOMED- stannous fluoride rinse 3M ESPE Dental Products Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies.
Frequently Asked Questions
This document provides answers to some common questions regarding the reporting of controlled substances to the New Hampshire (PDMP) database. A list of the questions answered in this document is provided